Please assess the completion status of the following clinical trial:

Trial Title: Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* successful coronary intervention \< 14 days~* regional contraction deficit of the left ventricle as detected either by echocardiography or cardiacMRI~* globally reduced ejection fraction (cardiac MRI or echocardiography: \< 60%)~* willing and able to cooperate~* voluntary participation~Exclusion Criteria:~* contraindication for cardiac MRI (i.e. pacemaker, ICD current or within the next 6 months, other metal implants)~* cardiogenic shock at time of inclusion~* uncontrolled hypertension (systolic blood pressure \> 180mmHg)~* hemoglobin \> 16mg/dl~* thrombocytosis~* malignant tumor~* missing informed consent~* renal failure (creatinine \> 300 mg/dl)~* liver failure~* other prognosis limiting, severe diseases (i.e. dementia)~* indication for open label erythropoietin treatment~* allergy towards solvents of the EPO preparation~* woman of childbearing potential~* other clinical study within the preceding 30days~* known alcohol or drug abuse~* neurologic or psychiatry disorders~* previous organ transplantation

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
- 2 (Type: PLACEBO_COMPARATOR): Placebo to erythropoetin beta.

Based on this trial design, predict the completion outcome and termination type (if applicable).